H-α-Asp-Lys-OH | 5891-51-0

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: H-α-Asp-Lys-OH
• 英文别名: L-Asp-L-Lys-OH；Asp-Lys；DK；Asp-Lys zwitterion；(2S)-6-azaniumyl-2-[[(2S)-2-azaniumyl-3-carboxylatopropanoyl]amino]hexanoate
• CAS: 5891-51-0
• 化学式: C₁₀H₁₉N₃O₅
• 分子量: 261.278
• InChiKey: OAMLVOVXNKILLQ-BQBZGAKWSA-N

物化性质

• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -6.6
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  156
• 氢给体数：
  5
• 氢受体数：
  7

制备方法与用途

Asp-Lys 是一种具有生物活性的肽。

反应信息

• 作为反应物：
  描述：

  H-α-Asp-Lys-OH 在 soybean cotyledon N-terminal acidic amino acid-specific aminopeptidase 作用下， 生成 L-赖氨酸 、 L-天门冬氨酸
  参考文献：
  名称：

  Purification and Characterization of an N-Terminal Acidic Amino Acid-Specific Aminopeptidase from Soybean Cotyledons (Glycine max)

  摘要：

  通过硫酸铵分级和 Q-sepharose、Phenyl sepharose 和 Superdex 200 连续柱层析，从大豆子叶中分离出一种催化 Glu-Glu 高效水解的新型酶。该酶的表观分子量为 56 kDa分别通过 SDS-聚丙烯酰胺凝胶电泳和 Superdex 200 HR 10/30 柱层析得出 510 kDa 和 510 kDa。该酶对 Glu-p-硝基苯胺 (pNA) 和 Asp-pNA 具有高活性，而 Leu-pNA、Phe-pNA、Ala-pNA 和 Pro-pNA 不被水解。合成的二肽 Glu-Xxx 和 Asp-Xxx 被水解，但 Xxx-Glu 没有被水解。使用这种纯化酶消化富含 Glu 的寡肽嗜铬粒蛋白 A (Glu-Glu-Glu-Glu-Glu-Met-Ala-Val-Val-Pro-Gln-Gly-Leu-Phe-Arg-Gly-NH2)也被调查。谷氨酸残基从N末端一一被切割。这些观察结果表明该酶从 N 末端含酸性氨基酸的肽中去除谷氨酰或天冬氨酰残基。人们认为它是一种来自植物的 N 末端酸性氨基酸特异性氨肽酶。

  DOI：

  10.1271/bbb.90617
• 作为产物：
  描述：

  N6-Cbz-L-赖氨酸 在 palladium on activated charcoal 氢气 、 三乙胺 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 52.0h， 生成 H-α-Asp-Lys-OH
  参考文献：
  名称：

  Synthesis and activity of NAcSerAspLysPro analogs on cellular interactions between T-cell and erythrocytes in rosette formation

  摘要：

  Analogues of NAcSerAspLysPro (AcSDKP), a natural regulator of hematopoiesis isolated from fetal calf bone marrow, were synthesized. The biological activity of these molecules were evaluated in vitro in the rosette assay, which measures the interaction between human Jurkat T-cells and sheep red blood cells. In this test, the tripeptide SerAspLys was the most efficient. Inhibitory activity was detected at the concentration 10(-14) M for the analogue and at 10(-9) M for the parent tetrapeptide. The dipeptide NAcSerAsp still showed activity but at much higher doses (10(-6) M). Substitution of polar amino acids led mostly to inactive molecules. Thus, replacement of Ser by Ala, or Lys by Orn yielded completely inactive compounds and replacement of Asp by Glu decreased the activity (10(-6) M). The present study gives an insight into the role of individual amino acids of AcSDKP in the inhibition of the rosette formation which implicates interactions with T-cell CD2 glycoprotein.

  DOI：

  10.1021/jm00170a012

文献信息

• [EN] COMBINING BETA-DIPEPTIDES AND AMINO ACIDS FOR OPTIMAL NUTRITIONAL SUPPLEMENTATION<br/>[FR] COMBINAISON DE BÊTA-DIPEPTIDES ET D'ACIDES AMINÉS POUR UN COMPLÉMENT NUTRITIONNEL OPTIMAL
  申请人：CYSAL GMBH

  公开号：WO2020025656A1

  公开（公告）日：2020-02-06

  The invention relates to anutritional supplement comprising a combination of one or more β-aspartyl-containing dipeptides,oroligomers thereof, or salts thereof, wherein each of the β-dipeptides comprises β-L-aspartyl as a first amino acid residue and an amino acid selected from arginine, lysine, ornithine, and citrulline as the second amino acid residue, and the respective second amino acid(s) or salts thereof. The invention further relates to the use of the combination for nutritional supplementation and to the combination for use in amino acid therapy.

  这项发明涉及一种营养补充剂，包括一种或多种β-天冬氨酰基二肽的组合，或其寡聚体，或其盐，其中每个β-二肽包括β-L-天冬氨酰作为第一个氨基酸残基，以及从精氨酸、赖氨酸、鸟氨酸和瓜氨酸中选择的氨基酸作为第二个氨基酸残基，以及相应的第二个氨基酸或其盐。该发明还涉及利用该组合进行营养补充以及用于氨基酸疗法的该组合。
• Modelling of prebiotic synthesis and selection of peptides under isothermal conditions and thermal cycling mode
  作者：O. V. Demina、A. S. Kononikhin、A. V. Laptev、A. A. Khodonov、E. N. Nikolaev、S. D. Varfolomeev

  DOI：10.1007/s11172-012-0060-3

  日期：2012.2

  The model peptide synthesis from mixtures of amino acids was carried out under the thermal cycling and isothermal modes. The compositions of the obtained mixtures of products and the primary amino acid sequence of the synthesized peptides were determined by Fourier transform ion cyclotron resonance mass spectrometry and tandem mass spectrometry in combination with high-performance liquid chromatography

  氨基酸混合物的模型肽合成在热循环和等温模式下进行。通过傅里叶变换离子回旋共振质谱和串联质谱结合高效液相色谱法，应用合成肽的从头测序，确定了所得产物混合物的组成和合成肽的一级氨基酸序列。产品。与可能的统计组相比，肽的天然合成过程显示在相对温和的温度条件下发生并且产生的肽数量显着减少。系统的演变发生在固相合成过程中，一系列最不稳定的肽消失了。
• MICROFLUIDIC PROTEIN CRYSTALLOGRAPHY
  申请人：Hansen Carl L.

  公开号：US20110306522A1

  公开（公告）日：2011-12-15

  The use of microfluidic structures enables high throughput screening of protein crystallization. In one embodiment, an integrated combinatoric mixing chip allows for precise metering of reagents to rapidly create a large number of potential crystallization conditions, with possible crystal formations observed on chip. In an alternative embodiment, the microfluidic structures may be utilized to explore phase space conditions of a particular protein crystallizing agent combination, thereby identifying promising conditions and allowing for subsequent focused attempts to obtain crystal growth.

  微流控结构的使用使得蛋白质结晶的高通量筛选成为可能。在一种实施方式中，集成的组合混合芯片允许精确计量试剂，以快速创建大量可能的结晶条件，并在芯片上观察到可能的晶体形成。在另一种实施方式中，微流控结构可以用于探索特定蛋白质结晶剂组合的相空间条件，从而确定有前途的条件，并允许随后集中尝试获得晶体生长。
• HIGH THROUGHPUT SCREENING OF CRYSTALLIZATION OF MATERIALS
  申请人：California Institute of Technology

  公开号：US20140041727A1

  公开（公告）日：2014-02-13

  High throughput screening of crystallization of a target material is accomplished by simultaneously introducing a solution of the target material into a plurality of chambers of a microfabricated fluidic device. The microfabricated fluidic device is then manipulated to vary the solution condition in the chambers, thereby simultaneously providing a large number of crystallization environments. Control over changed solution conditions may result from a variety of techniques, including but not limited to metering volumes of crystallizing agent into the chamber by volume exclusion, by entrapment of volumes of crystallizing agent determined by the dimensions of the microfabricated structure, or by cross-channel injection of sample and crystallizing agent into an array of junctions defined by intersecting orthogonal flow channels.

  通过将目标材料的溶液同时引入微型流体装置的多个腔室中，实现对目标材料结晶的高通量筛选。然后，操纵微型流体装置来改变腔室中的溶液条件，从而同时提供大量的结晶环境。改变溶液条件的控制可以采用各种技术，包括但不限于通过体积排斥将结晶剂体积计量到腔室中，通过微型加工结构的尺寸确定结晶剂体积的困扰，或通过交叉正交流道定义的连接点阵列中的样品和结晶剂的交叉通道注入。
• High throughput screening of crystallization materials
  申请人：California Institute of Technology, A California Corporation

  公开号：US20030061687A1

  公开（公告）日：2003-04-03

  High throughput screening of crystallization of a target material is accomplished by simultaneously introducing a solution of the target material into a plurality of chambers of a microfabricated fluidic device. The microfabricated fluidic device is then manipulated to vary the solution condition in the chambers, thereby simultaneously providing a large number of crystallization environments. Control over changed solution conditions may result from a variety of techniques, including but not limited to metering volumes of crystallizing agent into the chamber by volume exclusion, by entrapment of volumes of crystallizing agent determined by the dimensions of the microfabricated structure, or by cross-channel injection of sample and crystallizing agent into an array of junctions defined by intersecting orthogonal flow channels.

  目标材料结晶的高通量筛选是通过将目标材料溶液同时引入微型流体设备的多个腔室来实现的。然后操纵微型流体设备来改变腔室中的溶液条件，从而同时提供大量的结晶环境。对变化的溶液条件的控制可采用多种技术，包括但不限于通过体积排阻将结晶剂计量到腔室中，根据微制造结构的尺寸决定结晶剂的体积，或将样品和结晶剂跨通道注入由相交的正交流道定义的结点阵列中。